Mepolizumab reduces the need for surgery in patients with chronic rhinosinusitis with nasal polyps

Fokkens, Wytske J., Mullol, Joaquim, Kennedy, David W., Philpott, Carl ORCID: https://orcid.org/0000-0002-1125-3236, Seccia, Veronica, Kern, Robert, Coste, Andre, Sousa, Ana, Howarth, Peter, Benson, Victoria, Mayer, Bhabita, Yancey, Steve, Chan, Robert and Gane, Simon (2021) Mepolizumab reduces the need for surgery in patients with chronic rhinosinusitis with nasal polyps. In: UNSPECIFIED.

Full text not available from this repository. (Request a copy)

Abstract

Background: For patients with chronic rhinosinusitis with nasal polyps (CRSwNP), endoscopic sinus surgery (ESS) can be associated with high recurrence rates despite intranasal corticosteroids (as part of standard of care [SoC]). We assessed the impact of mepolizumab, a humanized anti-interleukin-5 antibody, on the need for repeat ESS in patients with CRSwNP. Methods: SYNAPSE, a randomized, double-blind, placebo-controlled, multicenter study, enrolled patients with CRSwNP uncontrolled with SoC. All patients had ≥1 ESS in the past 10 years and were eligible for repeat ESS. Patients received 4-weekly subcutaneous (SC) mepolizumab 100 mg or placebo, plus SoC, for 52 Weeks. We assessed the proportion of patients with a need for ESS (visual analog scale overall symptom score >7; endoscopic bilateral NP score ≥5), time to inclusion on a waiting list for ESS (Kaplan–Meier [KM] estimate), and the proportion of patients included on a waiting list, by Week 52. Results: Data from 407 patients (placebo n=201; mepolizumab n=206) were analyzed. Mean (SD) duration of CRSwNP was 11.4 (8.4) years; 218 (54%) patients had ≥2 ESS in the past 10 years. After 52 weeks, more patients using mepolizumab vs placebo were identified as not needing ESS (72% vs 51%, respectively; odds ratio [95% confidence interval] 2.46 [1.59, 3.79]; P<0.001). KM estimates indicated a ~50% lower risk of inclusion on a waiting list for ESS with mepolizumab than placebo. Up to Week 52, 16% vs 30% of patients using mepolizumab vs placebo were due for ESS on a waiting list. Conclusions: Mepolizumab 100 mg SC reduces the need for repeat surgery compared with placebo for patients with recurrent CRSwNP despite SoC therapy.

Item Type:	Conference or Workshop Item (Poster)
Uncontrolled Keywords:	otorhinolaryngology ,/dk/atira/pure/subjectarea/asjc/2700/2733
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Depositing User:	LivePure Connector
Date Deposited:	22 Jan 2021 01:03
Last Modified:	19 Oct 2023 04:02
URI:	https://ueaeprints.uea.ac.uk/id/eprint/78255
DOI:

Actions (login required)

View Item